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It is highly appreciated that the European Society of Medical Oncology has developed a system to 
assess new oncologic compounds according to their value to patients. Consequently,  offering 
decision-support to those who either want to use the new cancer therapies in clinical practice but 
cannot keep up-to-date with all therapy options or, alternatively,  to those who have to decide whether 
or not to fund new oncology  medicines or exclude from reimbursement due to their low value. This is 
particularly important with ever-rising prices for new oncology medicines which have increased up to 
ten fold in recent years.  
 
Having established a horizon-scanning system for new oncology medicines for Austria [1] since 2009, 
we have extensive experience with the early assessment of newly approved therapies for patients with 
cancer (n=59). Until recently, these assessments have not included recommendations.  We are now 
considering an adapted version of the ESMO-MCBS. With the aim of piloting and validating the 
ESMO-MCBS ± as suggested by Hartmann [2] - we ± 3 researchers, blinded to ESMO scores, blinded 
to each other´s scoring -  rated drugs in 3 indications (colorectal carcinoma, melanoma and lung 
cancer) which had been assessed by the Austrian HSO programme as well as having been scored by 
ESMO (n=11) (Table 1).  
 
  
Table 1: Adapted benefit assessment based on ESMO-MBSC 
 
 
 
In addition we discussed the ESMO-MCBS in a meeting of the Piperska-group for ³UDWLRQDO
SUHVFULELQJ´, a group of health authority personnel, advisers and academics from  across Europe 
involved with developing models to optimise the managed entry of new medicines [3, 4] and collected 
comments based on experiences with applying the proposed scores.  
 
Lastly, we compared our scoring with drug-assessments of several countries (IQWiG, NICE, HAS, 
SMC, pCODR,  etc.) [5] (table 2) and found a good correlation between oncology medicines scored 
with 1-2 on the ESMO-MCBS scale with oncology medicines not recommended for funding due to a 
lack of efficacy or poor cost-effectiveness. 
 
 
 
 
 
 
 
 
 
  
Table 2: Comparison of Scoring with HTA (and conditional agreements) 
Active 
substance 
Indication 
Pre-reimbursement assessments  
& Managed entry agreement 
 
HSO/ ESMO 
Aflibercept mCRC (2nd line) 
Germany (IQWIG): MI 
France ( HAS): ASMR 5 
England (NICE): NR 
Canada (pCODR): NR 
Belgium (RIZIV/INAMI): MEA 
Italy (AIFA): MEA 
Norway (NOKC): NL 
Poland (AOTMiT): PL 
Scotland (SMC): R 
 
 
1 (0)/1 
Regorafenib mCRC 
Germany (IQWIG): MI 
France ( HAS):  ASMR 5 
Canada (pCODR): NR 
Belgium (RIZIV/INAMI): MEA 
Poland (AOTMiT): NL 
 
1 (0)/1 
 
 
Nab-
Paclitaxel 
m adenocarcinoma of the pancreas 
(1st line) 
France ( HAS): ASMR 4 
England (NICE): NR 
Canada (pCODR):  CE-Ratio 
Belgium (RIZIV/INAMI): MEA 
Italy (AIFA): MEA 
Poland (AOTMiT): NL 
Scotland (SMC): R 
 
1/3 
Afatinib 
locally advanced/ mNSCLC  (1st 
line) 
Germany (IQWIG): CO 
France ( HAS): ASMR 5 
England (NICE): R 
Canada (pCODR):  CE-Ratio 
Italy (AIFA): MEA 
Poland (AOTMiT): PL 
Scotland (SMC): R 
 
3/4 
Crizotinib NSCLC (ALK positiv) (>1 Therapie) 
Germany (IQWIG): CO 
France ( HAS): ASMR 3 
England (NICE): NR 
Canada (pCODR): CE-Ratio 
Belgium (RIZIV/INAMI): MEA 
Italy (AIFA): MEA 
Poland (AOTMiT): NL 
Scotland (SMC): R 
 
3/4 
Erlotinib 
 
NSCLC (1st line) 
France ( HAS): ASMR 4 
England (NICE): R 
Belgium (RIZIV/INAMI): MEA 
Italy (AIFA): MEA 
WHO: NE 
Poland (AOTMiT): PL 
Scotland (SMC): R 
 
3(4)/4 
Gefitinib 
 
locally advanced/ m NSCLC 
(EGRF)  (1st line) 
France ( HAS): ASMR 4 
England (NICE): R 
Italy (AIFA): MEA 
WHO: NE 
Poland (AOTMiT): PL 
Scotland (SMC): R 
 
2/4 
Ipilimumab 
 
advanced & mMelanoma (1st line) 
Germany (IQWIG): NO 
France ( HAS): ASMR 5 
England (NICE): R 
Canada (pCODR): CE-Ratio 
Belgium (RIZIV/INAMI): MEA 
Italy (AIFA): MEA 
Poland (AOTMiT): PL 
Scotland (SMC): R 
 
1/3 
Nivolumab 
 
inoperable/ metastatic melanoma 
(1st line) 
Germany (IQWIG): CO 
Belgium (RIZIV/INAMI): MEA 
Norway (NOKC): PL 
Poland (AOTMiT): MEA 
Scotland (SMC): NR 
 
2/4 
Trametinib 
 
advanced/  mMelanoma  (BRAF 
V600 mutation) 
Germany (IQWIG): NO 
Canada (pCODR): CE-Ratio 
 
2/4 
Vemurafenib 
 
melanoma (BRAF V600 mutation) 
(1st line) 
France ( HAS): ASMR3 
England (NICE): R 
Canada (pCODR): CE-Ratio 
Belgium (RIZIV/INAMI): MEA 
Italy (AIFA): MEA 
Poland (AOTMiT):  MEA, CE-Ratio 
Scotland (SMC): R 
 
2/4 
NB. France: Improvement of Medical Benefit (ASMR) classification 1-5, 1= Major innovation, 2= Important 
improvement, 3= Significant improvement, 4= Minor improvement, 5=no improvement ; Germany: Added-benefit 
classification: MA =major, CO= considerable, MI=minor, NQ=not quantifiable, NO=no added-benefit; England, 
Canada: NR = not recommended, R = recommended; Canada, Poland: CE-ratio = not cost-effective, only with 
lower price; Belgium, Italy, Poland: MEA= Managed Entry Agreements; Norway, Poland: PL= positive list, NL = 
negative list; WHO: NE= not essential medicine 
 
We identified several limitations to the current ESMO-MCBS. Some of them have been pointed out 
and discussed already by others [2, 6, 7]. As a result, we propose adaptations due to perceived 
limitations which include: 
1. The use of the lower limit of the CI (confidence interval) rather than the point estimate  is not only 
introducing an optimistic perspective but is also systematically favouring drugs with a large CI and 
therefore a low certainty in results. We find the systematic bias not acceptable and not in 
concordance with standards for robust data in medical statistics and clinical epidemiology. 
2. The focus on primary endpoints even if they are surrogate endpoints is assigning PFS 
(progression-free-survival) an equal weight compared to the patient-relevant endpoints of OS 
(overall survival) and QoL (quality of life). This is not in accordance with HTA (health technology 
assessment) standards of using PRO (patient-relevant outcomes) as opposed to surrogate 
outcomes, which are most often not validated for their actual clinical relevance. This is especially 
important in solid tumours with concerns with translating surrogate markers into overall survival/ 
length of survival. 
3. The upgrading due to increased QoL, but only rarely the downgrading of cancer drugs due to  
worsened QoL or (S)$((serious adverse events) and/or increased discontinuation of therapy 
introduces again a bias towards an optimistic perspective concentrating on efficacy and ignoring 
risks and adverse events. 
4. Lastly, no rationale or weighted arguments are provided for the threshold-values. 
 
As seen in Table 1, our scores deviate from ESMO due to using the point estimate instead of using the 
lower limit of the CI. In addition, degrading because of (S)AE or if only data on PFS is available, rather 
than only upgrading because of an improvement in QoL, was done. Our re-calculated deviation is on 
average 1-2 scores lower than the ESMO scoring. We tried to extract as many data as possible in the 
table to show that even using the rationale of ESMO-MCBS, some of the (optimistic) ESMO-scores 
are not based on their own rules (alone) and some oncology medicines are upgraded without 
transparent reason. 
 
We therefore propose an adapted use of the ESMO-MCBS. This includes: 
x use of only OS data - if primary or secondary endpoint data is available;   
x use of only OS and QoL data in the non-curative (end of life) setting; 
x downgrade -1, if only data on surrogate endpoints is available;  
x use point estimates; 
x down-/upgrade due to toxicity(S)AE incl. reduction of OS or changes in QoL; 
x increase transparency with extracting SAE and therapy discontinuation data and reasons for up-/ 
downgrading. 
 
A structured and systematic approach that can discriminate between oncology medicines of higher 
value than others is most welcomed for assisting in the rational and appropriate use of limited public 
resources to deliver effective and affordable care. This is becoming more essential with increased 
prevalence rates world-wide. 
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